Conversion Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Retrospective Cohort Study.

IF 1.9 3区医学 Q3 ONCOLOGY

Journal of Surgical Oncology Pub Date : 2025-08-26 DOI:10.1002/jso.70068

Jienan Lu, Lusha Zhou, Shuai Zhang, Junxiu Li, Tanrong Liu, Bingying Huang

{"title":"Conversion Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Retrospective Cohort Study.","authors":"Jienan Lu, Lusha Zhou, Shuai Zhang, Junxiu Li, Tanrong Liu, Bingying Huang","doi":"10.1002/jso.70068","DOIUrl":null,"url":null,"abstract":"Background and objectives: Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant biliary tumor associated with a poor prognosis. Here, we explored conversion therapy (CT) for the treatment of locally advanced iCCA (LA-iCCA).Methods: We retrospectively enrolled 115 patients with LA-iCCA at our single center from January 2019 to June 2024, with the final follow-up conducted in January 2025. The primary outcome measured was overall survival (OS), while the secondary outcome focused on progression-free survival (PFS). We utilized a propensity score matching (PSM) approach to adjust for potential confounders between the CT group and the systemic therapy (ST) group.Results: Before PSM, the median OS was 34.57 months (95% CI: 19.22-49.91), while the median PFS was 17.30 months (95% CI: 12.89-21.71) in the CT group. Both OS and PFS were significantly longer than those in the ST group (both p < 0.001). After PSM, both groups were successfully matched, resulting in 31 patients in each group. In the CT group, the median OS and PFS were 45.53 months (95% CI: 29.19-61.87) and 18.23 months (95% CI: 7.02-29.45), respectively. Both values were significantly higher than those in the ST group, with P values of less than 0.001 for OS and 0.002 for PFS. Furthermore, CT was identified as an independent factor associated with improved outcomes, both before and after PSM.Conclusions: CT was an effective approach for improving outcomes in patients with LA-iCCA.","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jso.70068","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objectives: Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant biliary tumor associated with a poor prognosis. Here, we explored conversion therapy (CT) for the treatment of locally advanced iCCA (LA-iCCA).

Methods: We retrospectively enrolled 115 patients with LA-iCCA at our single center from January 2019 to June 2024, with the final follow-up conducted in January 2025. The primary outcome measured was overall survival (OS), while the secondary outcome focused on progression-free survival (PFS). We utilized a propensity score matching (PSM) approach to adjust for potential confounders between the CT group and the systemic therapy (ST) group.

Results: Before PSM, the median OS was 34.57 months (95% CI: 19.22-49.91), while the median PFS was 17.30 months (95% CI: 12.89-21.71) in the CT group. Both OS and PFS were significantly longer than those in the ST group (both p < 0.001). After PSM, both groups were successfully matched, resulting in 31 patients in each group. In the CT group, the median OS and PFS were 45.53 months (95% CI: 29.19-61.87) and 18.23 months (95% CI: 7.02-29.45), respectively. Both values were significantly higher than those in the ST group, with P values of less than 0.001 for OS and 0.002 for PFS. Furthermore, CT was identified as an independent factor associated with improved outcomes, both before and after PSM.

Conclusions: CT was an effective approach for improving outcomes in patients with LA-iCCA.

查看原文本刊更多论文

局部晚期肝内胆管癌的转化治疗：一项回顾性队列研究。

背景和目的：肝内胆管癌（iCCA）是一种预后较差的胆道高度恶性肿瘤。在这里，我们探讨了转换疗法（CT）治疗局部晚期iCCA （LA-iCCA）。方法：我们于2019年1月至2024年6月在我们的单中心回顾性招募了115例LA-iCCA患者，最后随访于2025年1月进行。主要终点是总生存期（OS），次要终点是无进展生存期（PFS）。我们使用倾向评分匹配（PSM）方法来调整CT组和全身治疗（ST）组之间潜在的混杂因素。结果：PSM前，CT组中位OS为34.57个月（95% CI: 19.22 ~ 49.91），中位PFS为17.30个月（95% CI: 12.89 ~ 21.71）。OS和PFS均明显长于ST组（均p）。结论：CT是改善LA-iCCA患者预后的有效方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Surgical Oncology 医学-外科

CiteScore

4.70

自引率

4.00%

发文量

367

审稿时长

2 months

期刊介绍： The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.